Qiagen

Thermo Fisher Scientific announced a proposal to acquire Qiagen for €39 per share in cash, valuing the transaction at approximately $11.5 billion including assumed debt.

Qiagen will commercialize NeuMoDx's PCR-based molecular diagnostic systems outside the U.S. and has an option to acquire all NeuMoDx shares not already owned for approximately $234 million, contingent on milestones.